BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRNBusiness Wire • 11/23/20
BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRNBusiness Wire • 11/21/20
BMRN FINAL DEADLINE: ROSEN, A RESPECTED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action - BMRNNewsfile Corp • 11/21/20
BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020Newsfile Corp • 11/20/20
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)Business Wire • 11/20/20
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 11/20/20
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 11/19/20
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRNPRNewsWire • 11/19/20
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial IntelligencePRNewsWire • 11/17/20
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 11/11/20
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
BioMarin Pharmaceutical (BMRN) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/05/20
ROSEN, A RESPECTED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRNNewsfile Corp • 11/04/20
Good News For BioMarin Pharmaceutical Comes With Caveat For Wary InvestorsInvestors Business Daily • 11/03/20
Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with AchondroplasiaPRNewsWire • 11/03/20
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BMRNPRNewsWire • 11/01/20
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRNPRNewsWire • 10/30/20
ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRNNewsfile Corp • 10/29/20
Were Hedge Funds Right About Souring On BioMarin Pharmaceutical Inc. (BMRN)?Insider Monkey • 10/27/20
